A Trial of Hetrombopag in Healthy Subjects

NCT05088174 | Completed Phase 1

• 1 other identifier: SHR8735-111
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, single-arm, open-label, self-controlled, phase I clinical study. A total of 26 male or female healthy subjects are intended to be enrolled to evaluate the PK drug-drug interaction between ciclosporin and hetrombopag.

Conditions

Sever Aplastic Anaemia

Outcome Measures

Primary Outcomes (3)

• Peak hetrombopag plasma concentration (Cmax)

  0-120 hours post dose

• Area Under the plasma hetrombopag concentration vs time curve (AUC0-120)

  0-120 hours post dose

• Area under the plasma hetrombopag concentration vs time curve (AUC0-inf)

  0-infinity

Secondary Outcomes (3)

• Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)

  0-120 hours post dose

• Half-life Associated With the Terminal Slope (t½)

  0-120 hours post dose

• The number of volunteers with adverse events as a measure of safety and tolerability

  up to Day 22

Study Arms (1)

D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine

EXPERIMENTAL

Drug: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule

Interventions

Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule DRUG

Drug: Hetrombopag Olamine Tablet Ciclosporin Soft Capsule

D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily sign the informed consent form prior to any study-related activities, understand the procedures and methods of the study, and agree to complete this study in strict accordance with the clinical study protocol;
• Male or female subjects aged 18-55 years (inclusive);
• Body mass index (BMI) between 18 and 26 kg/m2 (inclusive);
• Normal or abnormal but not clinically significant physical examination and laboratory test results; normal or abnormal but not clinically significant ECG;
• Have no plan for pregnancy and agree to take effective contraceptive measures from signing of informed consent form until 6 months after the last dose;
• Able to maintain a consistency of good communication with the investigators, and understand and comply with all the requirements of this study

You may not qualify if:

• Any previous or current serious clinical conditions of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, and hematological, immunological, psychiatric and metabolic abnormalities, or any disease that may interfere with the results of this study;
• History of deep venous thrombosis or other thrombotic disorders;
• QTc \> 450 ms in males or QTc \> 460 ms in females through 12-lead ECG examination with clinical significance per the investigator's judgment at screening;
• Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody (trust), or HIV antibody;
• Positive pregnancy test result;
• Allergic constitution, or allergy to any component of hetrombopag olamine tablets and ciclosporin capsules;
• Have received surgery within 4 weeks before the first study administration, or plan to undergo surgery during the course of the study;
• Have taken any drug that alters liver enzyme activity within 28 days before the first study administration or during the study;
• Have taken any prescription drug, over-the-counter drug, herbal medicine, or health supplements within 14 days before the first study administration, or within 5 half-lives of the drug at screening; plan to take non-study drugs or health supplements during the study;
• Consumption of grapefruit or grapefruit-containing products, foods or beverages containing caffeine, xanthine, or alcohol within 48 h before the first study administration; strenuous exercise, or other factors that affect drug absorption, distribution, metabolism, and excretion;
• Have participated in any drug clinical trial and have been treated with any investigational drug or medical device within 3 months before the first study administration (per the date of signing the informed consent form);
• Have blood donation (or blood loss) of ≥ 400 mL or have received blood transfusion within 3 months before screening;
• Unable or unwilling to comply with the lifestyle requirements in the protocol;
• Addicted to smoking (≥ 5 cigarettes per day within 1 month before screening);
• Average daily alcohol consumption of \> 15 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) and \> 25 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 1 month before screening;

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

West China Second University Hospital Ethics Committee

Chengdu, Sichuan, 610041, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 12, 2021
• First Posted: October 21, 2021
• Study Start: September 3, 2020
• Primary Completion: October 22, 2020
• Study Completion: October 22, 2020
• Last Updated: October 21, 2021

Record last verified: 2021-10

Locations

CN (1)